JDRF, Parker Institute for Cancer Immunotherapy, and the Helmsley Charitable Trust Form Cancer and Diabetes Research Initiative
What it is:
- JDRF, The Parker Institute for Cancer Immunotherapy, and The Leona M. and Harry B. Helmsley Charitable Trust today announced a collaborative research initiative to understand, predict and prevent insulin-dependent diabetes following checkpoint therapy for cancer.
- The three nonprofits are jointly funding $10 million in autoimmunity research over a three-year period.
Why it matters:
- Immunotherapy has become a first-line treatment for several types of cancer. Over time, researchers have observed that some patients develop autoimmune disorders following cancer immunotherapy.
- After treatment with checkpoint inhibitors, for example, roughly 1% develop a kind of insulin-dependent diabetes that appears similar to type 1 diabetes (T1D), according to research published in the journal Diabetes.
- The initiative represents the first time leading cancer immunotherapy and diabetes research organizations have come together to explore the intersection between these two types of chronic diseases.